Recherche dans les collections de brevets nationales et internationales
Une partie du contenu de cette demande n'est pas disponible pour le moment.
Si cette situation persiste, contactez-nous auObservations et contact
1. (WO1993016657) COMPOSITIONS CERAMIQUES INJECTABLES ET LEUR PROCEDE DE PREPARATION ET D'UTILISATION
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

WHAT IS CLAIMED IS:

1. An injectable implant composition
comprising a biocompatible ceramic matrix present in a pharmaceutically acceptable fluid carrier, wherein the ceramic matrix comprises particles having a size
distribution in the range from
50 μm to 250 μm.

2. An injectable implant composition as in claim 1, wherein the ceramic matrix is composed of calcium phosphate mineral particles.

3. An injectable implant composition as in claim 2, wherein the calcium phosphate mineral particles are composed of a material selected from the group consisting of sintered hydroxyapatite and tricalcium phosphate.

4. An injectable implant composition as in claim 2 , wherein the calcium phosphate mineral particles have enhanced surface porosity.

5. An injectable implant composition as in claim 1, wherein the ceramic matrix is present in the fluid carrier at a concentration from 0.75 gm/ml to 0.05 gm/ml.

6. An injectable implant composition as in claim 1, wherein the fluid carrier comprises a
biocompatible organic polymer which will dissipate from a tissue injection site, leaving the mineral particles.

7. An injectable implant composition as in claim 6, wherein the organic polymer is polyethylene glycol.

8. An injectable implant composition as in claim 1, further comprising collagen, wherein the ceramic matrix and collagen are suspended in an aqueous fluid carrier.

9. An injectable implant composition as in claim 8, wherein the ceramic matrix and the fibrillar collagen are present at a weight ratio in the range from 1:19 to 1:1 ceramic matrix : collagen.

10. An injectable implant composition as in claim 1, further comprising a biocompatible fluid
lubricant.

11. An injectable implant composition as in claim 10, wherein the biocompatible lubricant is glycerol or succinylated collagen.

12. An injectable implant composition as in claim 1, further comprising at least one positively charged biologically active substance.

13. An injectable implant composition as in claim 12, wherein the substance is a tissue growth factor.

14. A method for augmenting tissue in a living mammal, said method comprising subcutaneously injecting a composition including a ceramic matrix present in a pharmaceutically acceptable fluid carrier to a tissue site, wherein the ceramic matrix comprises particles having a size distribution in the range from 50 μm to 250 μm.

15. A method as in claim 14, wherein the tissue is soft tissue.

16. A method as in claim 14, wherein the
tissue is hard tissue.

17. A method as in claim 14, wherein the
> composition is injected using a 20 gauge or finer needle.

18. A method as in claim 14, wherein the
ceramic matrix is composed of calcium phosphate mineral
particles.

19. A method as in claim 16, wherein the
calcium phosphate mineral particles are composed of a
material selected from the group consisting of sintered
hydroxyapatite and tricalcium phosphate.

20. A method as in claim 14, wherein the
ceramic matrix is present in the fluid carrier at a
concentration from 0.75 gm/ml to 0.05 gm/ml.

21. A method as in claim 14, wherein the fluid carrier comprises a biocompatible organic polymer which
will dissipate from a tissue injection site, leaving the mineral particles.

5 22. A method as in claim 21, wherein the
organic polymer is a polyethylene glycol.

23. A method as in claim 14, further
comprising collagen, wherein the ceramic matrix and
0 collagen are suspended in an aqueous fluid carrier.

24. A method as in claim 23, wherein the
ceramic matrix and the collagen are present at a weight
ratio in the range from 1: 19 to 1:1 ceramic matrix :
5 collagen.

25. A method as in claim 14, wherein the composition further comprises a biocompatible fluid lubricant.

26. A method as in claim 25, wherein the biocompatible fluid lubricant is glycerol or succinylated collagen.

27. A method as in claim 14, wherein the composition further comprises at least one positively charged biologically active substance.

28. A method as in claim 25, wherej.n the substance is a tissue growth factor.

29. A method as in claim 14, wherein the tissue is bone and the composition further comprises a substance selected from the group consisting of
osteogenic factor and bone marrow.

30. A method for preparing injectable implant compositions, said method comprising combining a ceramic matrix in a pharmaceutically acceptable fluid carrier, wherein the ceramic matrix comprises particles having a size distribution in the range from 50 μm to 250 μm.

31. A method as in claim 30, wherein the ceramic matrix particles are treated to enhance surface porosity prior for combination with the fluid carrier.

32. A method as in claim 30, wherein the ceramic matrix is composed of calcium phosphate mineral particles.

33. A method as in claim 30, wherein the calcium phosphate mineral particles are composed of a material selected from the group consisting of sintered hydroxyapatite and tricalcium phosphate.

34. A method as in claim 30, wherein the ceramic matrix is combined in the fluid carrier at a concentration from 0.75 gm/ml to 0.05 gm/ml.

35. A method as in claim 30, wherein the fluid carrier comprises a biocompatible organic polymer which will dissipate from a tissue injection site, leaving the mineral particles,

36. A method as in claim 35, wherein the organic polymer is a polyethylene glycol.

37. A method as in claim 30, further
comprising combining collagen, wherein the ceramic matrix and collagen are suspended in an aqueous fluid carrier.

38. A method as in claim 34, wherein the ceramic matrix and the collagen are combined at a weight ratio in the range from 1:19 to 1:1 ceramic matrix :
collagen.

39. A method as in claim 30, further
comprising combining the pharmaceutically acceptable fluid carrier with a biocompatible fluid lubricant.

40. A method as in claim 39, wherein the biocompatible fluid lubricant is glycerol of succinylated collagen.

41. A method as in claim 30, further
comprising combining least one biologically active substance.

42. A method as in claim 41, wherein the
substance is selected from the group consisting of tissue growth factors, osteogenic factors, and bone marrow.

> 43. A kit comprising:
a syringe loaded with a volume of a
biocompatible ceramic matrix including particles having a size distribution in the range from 50 μm to 250 μm
present in a fluid carrier.